Koyfin Home > Directory > Health Care > Nymox Pharm Corp > EBITDA / Interest Expenses

Nymox Pharm Corp EBITDA / Interest Expenses Chart (NYMX)

Nymox Pharm Corp annual/quarterly EBITDA / Interest Expenses from 2010 to 2020. EBITDA / Interest is the interest coverage ratio and measures the ability of a company to service its debt.
  • Nymox Pharm Corp EBITDA / Interest Expenses for the quarter ending June 06, 2020 was $-350m a -26.59% increase of 93m year over year
  • Nymox Pharm Corp EBITDA / Interest Expenses for the last 12 months ending June 06, 2020 was $-269m a -171.25% increase of 460m year over year
  • Nymox Pharm Corp Annual EBITDA / Interest Expenses for 2019 was $-329m a -79.56% increase of 262m from 2018
  • Nymox Pharm Corp Annual EBITDA / Interest Expenses for 2018 was $-591m a 56.94% decrease of -337m from 2017
  • Nymox Pharm Corp Annual EBITDA / Interest Expenses for 2017 was $-255m a 57.16% decrease of -145m from 2016
Other Ratios Metrics:
  • Nymox Pharm Corp Total Debt / Capital for the quarter ending September 09, 2017 was $98m a 78.16% increase of 77m year over year
  • Nymox Pharm Corp Other Liabilities for the quarter ending December 12, 2016 was $0m a 208,053.10% decrease of -2m year over year
  • Nymox Pharm Corp Total Debt / Equity for the quarter ending September 09, 2017 was $6,192m a 99.37% increase of 6,153m year over year
View Chart On Koyfin

Quarterly NYMX EBITDA / Interest Expenses Data

06/2020$-350m
12/2019$-55m
12/2018$-153m
03/2018$-443m
09/2017$-304m
06/2017$-24m
03/2017$-53m
09/2016$-39m
06/2016$-70m
03/2016$-56m

Annual NYMX EBITDA / Interest Expenses Data

2019$-329m
2018$-591m
2017$-255m
2016$-109m
2015$-192m
2014$-299m
2013$-551m
2012$-713m
2011$-821m
2010$-918m